Comparative evaluation of the efficacy, safety, and tolerability of rosuvastatin 10 mg with atorvastatin 10 mg in adult patients with hypercholesterolaemia: the first Indian study.
J Indian Med Assoc
;
2004 Jan; 102(1): 48-50, 52
Artículo
en Inglés
| IMSEAR
| ID: sea-102403
ABSTRACT
To compare the efficacy, safety and tolerability of rosuvastatin 10mg with atorvastatin 10 mg in adult Indian patients with hypercholesterolaemia, a prospective, open-label, comparative, phase III study was conducted. A total of 45 patients of either sex, between 18 and 80 years of age with hypercholesterolaemia, having LDL cholesterol (LDL-C) of 160 and < 250 mg/dl and triglyceride < 400 mg/dl, were included in this trial. After a dietary run-in period of 2 weeks, patients received either rosuvastatin 10 mg once daily or atorvastatin 10 mg once daily, for 6 weeks. The fall in the mean LDL-C levels after 6 weeks of treatment in rosuvastatin group (40.1%) was significantly more as compared to the fall in atorvastatin group (29.8%). Other secondary lipid parameters like total cholesterol (TC), HDL cholesterol (HDL-C), triglycerides, apo-B, apo-AI, and TC/HDL-C ratio also showed more beneficial changes from the baseline in rosuvastatin group than in atorvastatin group. Rosuvastatin 10 mg shows significantly better efficacy than atorvastatin 10 mg in reducing LDL-C levels and produces greater improvements in other elements of the lipid profile.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Asunto principal:
Apolipoproteínas B
/
Pirimidinas
/
Pirroles
/
Sulfonamidas
/
Femenino
/
Humanos
/
Masculino
/
Colesterol
/
Estudios Prospectivos
/
Inhibidores de Hidroximetilglutaril-CoA Reductasas
Tipo de estudio:
Ensayo Clínico Controlado
/
Estudio observacional
Idioma:
Inglés
Revista:
J Indian Med Assoc
Año:
2004
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS